{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T01:33:57Z","timestamp":1783388037502,"version":"3.54.6"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T00:00:00Z","timestamp":1662508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T00:00:00Z","timestamp":1662508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s40121-022-00685-x","type":"journal-article","created":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T13:02:51Z","timestamp":1662555771000},"page":"2035-2043","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Post-marketing Surveillance of a Quadrivalent Influenza Vaccine (Vaxigrip\u00a0Tetra) in South Korea"],"prefix":"10.1007","volume":"11","author":[{"given":"Sookyung","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Syrkina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,7]]},"reference":[{"issue":"5","key":"685_CR1","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3961\/jpmph.19.156","volume":"52","author":"K Hong","year":"2019","unstructured":"Hong K, Sohn S, Chun BC. Estimating Influenza-associated Mortality in Korea: the 2009\u20132016 Seasons. J Prev Med Public Health. 2019;52(5):308\u201315.","journal-title":"J Prev Med Public Health"},{"key":"685_CR2","unstructured":"Chungmin P, Gyehee L, Hyengil C, Jeongsuk S, Donghan L. Estimation of excess mortality associated with influenzas in Korea. Cheongju: Korea Disease Control and Prevention Agency (KDCA); 2021. p. 1157\u201361."},{"issue":"4","key":"685_CR3","doi-asserted-by":"publisher","first-page":"e111","DOI":"10.1016\/j.amepre.2015.09.028","volume":"50","author":"M Park","year":"2016","unstructured":"Park M, Wu P, Goldstein E, Kim WJ, Cowling BJ. Influenza-associated excess mortality in South Korea. Am J Prev Med. 2016;50(4):e111\u20139.","journal-title":"Am J Prev Med"},{"issue":"3","key":"685_CR4","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/nrd4529","volume":"14","author":"F Krammer","year":"2015","unstructured":"Krammer F, Palese P. Advances in the development of influenza virus vaccines. Nat Rev Drug Discov. 2015;14(3):167\u201382.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"685_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12985-017-0918-y","volume":"15","author":"GA Sautto","year":"2018","unstructured":"Sautto GA, Kirchenbaum GA, Ross TM. Towards a universal influenza vaccine: different approaches for one goal. Virol J. 2018;15(1):17.","journal-title":"Virol J"},{"key":"685_CR6","unstructured":"WHO. Influenza. 2022. https:\/\/www.who.int\/teams\/immunization-vaccines-and-biologicals\/diseases\/seasonal-influenza."},{"issue":"5","key":"685_CR7","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1093\/aje\/kwaa196","volume":"190","author":"V Cozza","year":"2021","unstructured":"Cozza V, Campbell H, Chang HH, et al. Global seasonal influenza mortality estimates: a comparison of 3 different approaches. Am J Epidemiol. 2021;190(5):718\u201327.","journal-title":"Am J Epidemiol"},{"issue":"Suppl 1","key":"685_CR8","doi-asserted-by":"publisher","first-page":"A6","DOI":"10.1016\/j.vaccine.2020.09.048","volume":"39","author":"AE Macias","year":"2021","unstructured":"Macias AE, McElhaney JE, Chaves SS, et al. The disease burden of influenza beyond respiratory illness. Vaccine. 2021;39(Suppl 1):A6\u201314.","journal-title":"Vaccine"},{"issue":"10334","key":"685_CR9","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/S0140-6736(22)00383-X","volume":"399","author":"MC Swets","year":"2022","unstructured":"Swets MC, Russell CD, Harrison EN, et al. SARS-CoV-2 co-infection with influenza viruses, respiratory syncytial virus, or adenoviruses. Lancet. 2022;399(10334):1463\u20134.","journal-title":"Lancet"},{"issue":"13","key":"685_CR10","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1001\/jama.2020.14661","volume":"324","author":"DA Solomon","year":"2020","unstructured":"Solomon DA, Sherman AC, Kanjilal S. Influenza in the COVID-19 era. JAMA. 2020;324(13):1342\u20133.","journal-title":"JAMA"},{"key":"685_CR11","unstructured":"CDC. People at higher risk of flu complications. Atlanta: Centers for Disease Control and Prevention (CDC); 2021. https:\/\/www.cdc.gov\/flu\/highrisk\/index.htm."},{"key":"685_CR12","unstructured":"CDC. Similarities and differences between flu and COVID-19. Atlanta: Centers for Disease Control and Prevention (CDC); 2022. https:\/\/www.cdc.gov\/flu\/symptoms\/flu-vs-covid19.htm."},{"key":"685_CR13","unstructured":"WHO. Coronavirus disease (COVID-19) pandemic. Coronavirus disease (COVID-19); 2022. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019."},{"issue":"1","key":"685_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12998\/wjcc.v10.i1.1","volume":"10","author":"SY Ren","year":"2022","unstructured":"Ren SY, et al. Omicron variant (B.1.1.529) of SARS-CoV-2: mutation, infectivity, transmission, and vaccine resistance. World J Clin Cases. 2022;10(1):1\u201311.","journal-title":"World J Clin Cases"},{"key":"685_CR15","unstructured":"ECDC. Clinical characteristics of COVID-19. Stockholm: European Centre for Disease Prevention and Control; 2021. https:\/\/www.ecdc.europa.eu\/en\/covid-19\/latest-evidence\/clinical"},{"issue":"4","key":"685_CR16","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41591-021-01283-z","volume":"27","author":"A Nalbandian","year":"2021","unstructured":"Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601\u201315.","journal-title":"Nat Med"},{"issue":"1","key":"685_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14760584.2018.1407650","volume":"17","author":"V Gresset-Bourgeois","year":"2018","unstructured":"Gresset-Bourgeois V, Leventhal PS, Pepin S, et al. Quadrivalent inactivated influenza vaccine (VaxigripTetra). Expert Rev Vaccines. 2018;17(1):1\u201311.","journal-title":"Expert Rev Vaccines"},{"issue":"3","key":"685_CR18","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1080\/21645515.2017.1381808","volume":"14","author":"WS Choi","year":"2018","unstructured":"Choi WS, Noh JY, Lee J, et al. Immunogenicity and safety of a split-virion quadrivalent influenza vaccine in adults 18\u201360 years of age in the Republic of Korea. Hum Vaccines Immunother. 2018;14(3):587\u201392.","journal-title":"Hum Vaccines Immunother"},{"key":"685_CR19","unstructured":"MFDS. Standard for re-examination of new drugs. Cheongju: Korean Ministry of Food and Drug Safety; 2020."},{"issue":"3","key":"685_CR20","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1080\/21645515.2020.1795477","volume":"17","author":"VD Thiem","year":"2021","unstructured":"Thiem VD, Chabanon A-L, Fournier M, et al. Safety of a quadrivalent influenza vaccine in Vietnamese healthy subjects aged 6 months and older. Hum Vaccines Immunother. 2021;17(3):690\u20133.","journal-title":"Hum Vaccines Immunother"},{"issue":"21","key":"685_CR21","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1016\/j.vaccine.2015.03.065","volume":"33","author":"JB Cadorna-Carlos","year":"2015","unstructured":"Cadorna-Carlos JB, Nolan T, Borja-Tabora CF, et al. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: a randomized, controlled, phase III trial. Vaccine. 2015;33(21):2485\u201392.","journal-title":"Vaccine"},{"issue":"12","key":"685_CR22","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1080\/21645515.2016.1212143","volume":"12","author":"S Pepin","year":"2016","unstructured":"Pepin S, Szymanski H, Kobashi IAR, et al. Safety and immunogenicity of an intramuscular quadrivalent influenza vaccine in children 3 to 8\u00a0y of age: a phase III randomized controlled study. Hum Vaccines Immunother. 2016;12(12):3072\u20138.","journal-title":"Hum Vaccines Immunother"},{"issue":"4","key":"685_CR23","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1080\/21645515.2020.1804247","volume":"17","author":"L Serradell","year":"2021","unstructured":"Serradell L, Wagu\u00e9 S, Moureau A, Nissil\u00e4 M, Chabanon A-L. Enhanced passive safety surveillance of a trivalent and a quadrivalent influenza vaccine in Denmark and Finland during the 2018\/2019 season. Hum Vaccines Immunother. 2021;17(4):1205\u201310.","journal-title":"Hum Vaccines Immunother"},{"issue":"1","key":"685_CR24","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1186\/s12889-021-10378-8","volume":"21","author":"AL Chabanon","year":"2021","unstructured":"Chabanon AL, Wague S, Moureau A, Nissila M, Serradell L. Enhanced passive safety surveillance of the quadrivalent inactivated split-virion influenza vaccine (IIV4) in Finland during the 2019\/20 influenza season. BMC Public Health. 2021;21(1):358.","journal-title":"BMC Public Health"},{"issue":"9","key":"685_CR25","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1080\/21645515.2019.1581538","volume":"15","author":"S Gandhi-Banga","year":"2019","unstructured":"Gandhi-Banga S, Chabanon A-L, Eymin C, Caroe T, Butler K, Moureau A. Enhanced passive safety surveillance of three marketed influenza vaccines in the UK and the Republic of Ireland during the 2017\/18 season. Hum Vaccines Immunother. 2019;15(9):2154\u20138.","journal-title":"Hum Vaccines Immunother"},{"issue":"1","key":"685_CR26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/vaccines6010014","volume":"6","author":"E Montomoli","year":"2018","unstructured":"Montomoli E, Torelli A, Manini I, Gianchecchi E. Immunogenicity and safety of the new inactivated quadrivalent influenza vaccine Vaxigrip Tetra: preliminary results in children >\/=\u20096\u00a0months and older adults. Vaccines (Basel). 2018;6(1):14.","journal-title":"Vaccines (Basel)"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-022-00685-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-022-00685-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-022-00685-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T17:42:10Z","timestamp":1667065330000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-022-00685-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,7]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["685"],"URL":"https:\/\/doi.org\/10.1007\/s40121-022-00685-x","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,7]]},"assertion":[{"value":"4 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}